Aging Brain Changes, Executive Dysfunction and Depression (FA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00918684|
Recruitment Status : Completed
First Posted : June 11, 2009
Results First Posted : May 12, 2017
Last Update Posted : May 12, 2017
|Condition or disease||Intervention/treatment||Phase|
|Depression||Drug: Escitalopram||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||116 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Aging White Matter Changes, Executive Dysfunction and Depression|
|Actual Study Start Date :||December 2002|
|Actual Primary Completion Date :||May 2010|
|Actual Study Completion Date :||May 2010|
12-week open label with 2 week placebo period (14 weeks total)
10mg tab daily
Other Name: Lexapro
- Hamilton Depression Rating Scale. [ Time Frame: 14 weeks (12th week of treatment) ]A published and widely-used scale for rating depression severity, the Hamilton Depression Rating Scale 24 item total scores range from 0-76. Higher scores indicate greater severity of depression. Total scores are reported with no subscales.
- WHODAS-II Disability Scale [ Time Frame: 14 weeks (12th week of treatment) ]A disability rating scale published by the World Health Organization, the WHODAS II total scores can range from 0-100. Higher scores indicate greater severity of disability. Total scores are reported with no subscales.
- Stroop Color-Word Test [ Time Frame: 14 weeks (12th week of treatment) ]A published and widely used executive dysfunction test, the Stroop Color-Word total scores can range from 0-100. Higher scores indicate better memory functioning (no cognitive impairment). Total scores are reported with no subscales.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00918684
|Principal Investigator:||George S Alexopoulos, MD||Weill Medical College of Cornell University|